BioMarin Pharmaceutical vs Bio-Techne

BioMarin Pharmaceutical (BMRN), health care, and Bio-Techne (TECH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

BioMarin Pharmaceutical and Bio-Techne are valued at about the same: $11.3B and $11.4B. BioMarin Pharmaceutical's operating margin in its latest fiscal year was 12.7% and Bio-Techne's 20.7%. Over the past year BioMarin Pharmaceutical's share price has moved +7.07% and Bio-Techne's +25.2%.

Key facts

BioMarin Pharmaceutical market value
$11.3B
Bio-Techne market value
$11.4B
Bio-Techne P/E
66.7
BioMarin Pharmaceutical revenue
$3.2BFY to 2025-12-31
Bio-Techne revenue
$1.2BFY to 2026-06-30
Superinvestors holding both
0

Market values as of .

BioMarin Pharmaceutical vs Bio-Techne: every measure side by side
Measure BioMarin Pharmaceutical Bio-Techne
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312026-06-30
Size
Market cap$11.3Blower$11.4Bhigher
Revenue$3.2Bhigher$1.2Blower
Earnings$348.9Mhigher$181.9Mlower
Employees3,221higher3,000lower
Total assets$7.6Bhigher$2.6Blower
Valuation
P/E—66.7
P/S3.5lower9.4higher
P/B1.8lower5.3higher
Dividend yield0.00%lower0.33%higher
Profitability
Operating margin12.7%lower20.7%higher
Balance sheet
Net assets$6.1Bhigher$2.1Blower
Total liabilities$1.5Bhigher$478.5Mlower
Total debt—$200M
Cash on hand$1.3Bhigher$264.7Mlower
Price change
Today+0.76%higher-0.06%lower
1 year+7.07%lower+25.2%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

BioMarin Pharmaceutical only (3)

Percentages are each holding's share of that investor's reported portfolio. Who owns BMRN · Who owns TECH

Further comparisons

Learn

Questions and answers

Which is bigger, BioMarin Pharmaceutical or Bio-Techne?

By market value, Bio-Techne is the larger: $11.4B against $11.3B for BioMarin Pharmaceutical. By revenue in its latest fiscal year, BioMarin Pharmaceutical is the larger: $3.2B against $1.2B for Bio-Techne.

Which has the higher operating margin?

Bio-Techne: 20.7%, against 12.7% for BioMarin Pharmaceutical. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Bio-Techne: 0.33%, against 0.00% for BioMarin Pharmaceutical. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both BioMarin Pharmaceutical and Bio-Techne?

None of the tracked superinvestors holds both in their latest 13F filing. 3 hold BioMarin Pharmaceutical and 7 hold Bio-Techne.

Cite this page

Funkfolio, “BioMarin Pharmaceutical vs Bio-Techne”, data as of 17 November 2026. https://funkfolio.com/compare/bmrn-vs-tech

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.